Glenview State Bank Trust Lowered General Electric Co (GE) Holding by $1.17 Million; Mpm Asset Management Increases Stake in Conatus Pharmaceuticals (CNAT)

May 16, 2018 - By Michael Collier

General Electric Company (NYSE:GE) Logo

Glenview State Bank Trust decreased its stake in General Electric Co (GE) by 51.37% based on its latest 2017Q4 regulatory filing with the SEC. Glenview State Bank Trust sold 68,737 shares as the company’s stock declined 23.20% with the market. The institutional investor held 65,079 shares of the consumer electronics and appliances company at the end of 2017Q4, valued at $1.14M, down from 133,816 at the end of the previous reported quarter. Glenview State Bank Trust who had been investing in General Electric Co for a number of months, seems to be less bullish one the $130.54B market cap company. The stock increased 2.18% or $0.32 during the last trading session, reaching $15.03. About 51.07 million shares traded. General Electric Company (NYSE:GE) has declined 54.35% since May 16, 2017 and is downtrending. It has underperformed by 65.90% the S&P500.

Mpm Asset Management Llc increased its stake in Conatus Pharmaceuticals Inc. (CNAT) by 76.26% based on its latest 2017Q4 regulatory filing with the SEC. Mpm Asset Management Llc bought 909,091 shares as the company’s stock rose 13.83% while stock markets declined. The institutional investor held 2.10M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $9.71M, up from 1.19M at the end of the previous reported quarter. Mpm Asset Management Llc who had been investing in Conatus Pharmaceuticals Inc. for a number of months, seems to be bullish on the $115.14M market cap company. The stock increased 3.23% or $0.12 during the last trading session, reaching $3.83. About 384,277 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 12.92% since May 16, 2017 and is uptrending. It has outperformed by 1.37% the S&P500.

Investors sentiment decreased to 1.1 in Q4 2017. Its down 0.73, from 1.83 in 2017Q3. It is negative, as 14 investors sold CNAT shares while 17 reduced holdings. 11 funds opened positions while 23 raised stakes. 11.71 million shares or 7.58% more from 10.89 million shares in 2017Q3 were reported. United Cap Advisers Limited Liability Co invested in 0.01% or 314,955 shares. Macquarie Grp Inc reported 0% stake. Moreover, Vanguard Gru has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 16,800 shares. D E Shaw & Company has 45,382 shares. Financial Bank Of Ny Mellon invested in 215,843 shares or 0% of the stock. Strs Ohio reported 26,700 shares. Royal Retail Bank Of Canada invested in 0% or 1,143 shares. Ameritas Invest Prtnrs Inc invested in 2,246 shares or 0% of the stock. Tiaa Cref Inv Management Limited Liability owns 216,766 shares. Aqr Mgmt Limited Liability has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 734,261 shares. Reilly Fincl Advsrs Ltd stated it has 22,011 shares. Arrowstreet Partnership accumulated 141,700 shares or 0% of the stock. Panagora Asset Mngmt Incorporated accumulated 152,975 shares. Voya Investment Mngmt Limited Com holds 14,517 shares or 0% of its portfolio.

Among 7 analysts covering Conatus Pharma (NASDAQ:CNAT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma had 17 analyst reports since September 22, 2015 according to SRatingsIntel. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by Oppenheimer on Thursday, March 1. H.C. Wainwright maintained the shares of CNAT in report on Tuesday, December 20 with “Buy” rating. As per Wednesday, November 9, the company rating was maintained by Stifel Nicolaus. The stock has “Buy” rating by H.C. Wainwright on Thursday, April 5. The rating was maintained by Oppenheimer on Thursday, March 22 with “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, December 20. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by Roth Capital on Friday, July 1. The company was maintained on Wednesday, March 7 by Oppenheimer. Stifel Nicolaus maintained the shares of CNAT in report on Thursday, November 5 with “Buy” rating. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by Oppenheimer on Thursday, May 3.

More news for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were recently published by: Seekingalpha.com, which released: “Your Daily Pharma Scoop: Conatus Data, Solid Biosciences’ SGT-001, Ultragenyx’s Crysvita Approved” on April 19, 2018. Nasdaq.com‘s article titled: “Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with …” and published on April 30, 2018 is yet another important article.

Analysts await General Electric Company (NYSE:GE) to report earnings on July, 20. They expect $0.18 earnings per share, down 35.71% or $0.10 from last year’s $0.28 per share. GE’s profit will be $1.56B for 20.88 P/E if the $0.18 EPS becomes a reality. After $0.16 actual earnings per share reported by General Electric Company for the previous quarter, Wall Street now forecasts 12.50% EPS growth.

Glenview State Bank Trust, which manages about $216.84M US Long portfolio, upped its stake in Becton Dickinson Co (NYSE:BDX) by 3,958 shares to 10,898 shares, valued at $2.33 million in 2017Q4, according to the filing.

More notable recent General Electric Company (NYSE:GE) news were published by: Marketwatch.com which released: “GE’s stock survived the battle of the ‘breakaway gap,’ and that may have won bulls the war” on May 11, 2018, also Seekingalpha.com with their article: “General Electric’s Death Could Be Best For Shareholders” published on April 25, 2018, Seekingalpha.com published: “GE: The Bottom Appears To Be In; Near-Term Upside Potential 35-50%” on May 15, 2018. More interesting news about General Electric Company (NYSE:GE) were released by: Seekingalpha.com and their article: “Gabelli on GE: ‘There is a way out'” published on May 14, 2018 as well as Investorplace.com‘s news article titled: “5 Top Stock Trades for Thursday Morning” with publication date: May 16, 2018.

Since January 26, 2018, it had 1 insider buy, and 0 selling transactions for $43,446 activity.

Investors sentiment decreased to 0.5 in 2017 Q4. Its down 0.19, from 0.69 in 2017Q3. It fall, as 153 investors sold GE shares while 921 reduced holdings. 151 funds opened positions while 383 raised stakes. 4.69 billion shares or 0.29% less from 4.70 billion shares in 2017Q3 were reported. Selway Asset Mngmt reported 0.49% in General Electric Company (NYSE:GE). Strategic Advisors Limited Liability Com holds 10,449 shares. Peapack Gladstone Fincl Corp accumulated 726,396 shares or 0.68% of the stock. Bb&T has 0.28% invested in General Electric Company (NYSE:GE). Bourgeon Cap Management Limited Liability Company owns 0.2% invested in General Electric Company (NYSE:GE) for 21,371 shares. Ing Groep Nv reported 0.3% in General Electric Company (NYSE:GE). North Star Asset Management Inc owns 234,907 shares. Ironwood Counsel Ltd stated it has 471,847 shares. Dsc Advsrs Lp, Illinois-based fund reported 12,277 shares. Smithfield accumulated 264,476 shares. Bbva Compass Financial Bank has invested 0.15% in General Electric Company (NYSE:GE). State Of New Jersey Common Pension Fund D invested 0.47% of its portfolio in General Electric Company (NYSE:GE). Mariner Wealth Ltd invested in 0.18% or 266,224 shares. Moller Fincl stated it has 36,544 shares. Gfs Ltd Liability owns 855,207 shares.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>